Celosia Therapeutics has begun dosing the first participant in its Phase 1b KOANEWA trial to test CTx1000, a gene therapy designed to clear pathological TDP-43 protein, a key driver of amyotrophic lateral sclerosis (ALS). This first-in-human study at Macquarie University Hospital in Sydney aims to evaluate the safety and tolerability of a single dose of CTx1000 in ALS patients, with secondary measures assessing biomarkers and clinical effects. The therapy builds on a 2024 discovery of a unique binder to TDP-43, showing promise in preclinical models for halting and partially reversing ALS progression. This trial marks a significant step toward a potential disease-modifying treatment for ALS, which currently has limited options.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
